Your browser is no longer supported. Please, upgrade your browser.
Settings
AEZS [NASD]
Aeterna Zentaris Inc.
Index- P/E- EPS (ttm)-0.20 Insider Own0.60% Shs Outstand95.44M Perf Week-16.50%
Market Cap111.05M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float62.62M Perf Month-16.50%
Income-7.30M PEG- EPS next Q- Inst Own21.40% Short Float9.79% Perf Quarter-72.50%
Sales3.10M P/S35.82 EPS this Y63.90% Inst Trans0.86% Short Ratio0.42 Perf Half Y187.03%
Book/sh0.67 P/B1.37 EPS next Y- ROA-16.90% Target Price- Perf Year-12.52%
Cash/sh0.61 P/C1.51 EPS next 5Y- ROE-31.40% 52W Range0.29 - 3.62 Perf YTD115.86%
Dividend- P/FCF- EPS past 5Y63.10% ROI-45.90% 52W High-74.63% Beta1.91
Dividend %- Quick Ratio15.70 Sales past 5Y46.30% Gross Margin52.90% 52W Low216.72% ATR0.09
Employees11 Current Ratio15.70 Sales Q/Q-45.50% Oper. Margin- RSI (14)42.42 Volatility6.98% 9.66%
OptionableYes Debt/Eq0.00 EPS Q/Q-142.50% Profit Margin- Rel Volume0.09 Prev Close0.96
ShortableYes LT Debt/Eq0.00 EarningsMay 05 BMO Payout- Avg Volume14.43M Price0.92
Recom- SMA20-6.85% SMA50-15.58% SMA20031.92% Volume1,321,067 Change-3.98%
Jul-19-17Reiterated Maxim Group Buy $2 → $4
May-10-17Reiterated H.C. Wainwright Buy $7.50 → $3
May-01-17Reiterated Maxim Group Buy $11 → $2
Jan-17-17Reiterated Maxim Group Buy $7 → $10
Dec-02-15Reiterated H.C. Wainwright Buy $11 → $12
Nov-24-15Reiterated H.C. Wainwright Buy $0.11 → $11
Nov-23-15Reiterated Maxim Group Buy $200 → $11
Apr-14-15Upgrade H.C. Wainwright Neutral → Buy $1.25
Nov-06-14Downgrade H.C. Wainwright Buy → Neutral
Jul-17-14Initiated H.C. Wainwright Buy $3
Jan-03-13Upgrade MLV & Co Hold → Buy $5.50
Oct-09-12Initiated Maxim Group Buy $9
Apr-02-12Downgrade MLV & Co Buy → Hold
Jun-07-11Initiated Oppenheimer Outperform $5.50
Apr-27-11Reiterated Canaccord Genuity Speculative Buy $2.75 → $4
Nov-29-10Initiated MLV Capital Buy $5.50
Feb-05-09Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-03-08Reiterated Canaccord Adams Buy $3.20 → $2.65
Apr-14-08Reiterated Canaccord Adams Buy $4.50 → $3.20
Oct-03-07Reiterated Rodman & Renshaw Mkt Outperform $8 → $6
May-10-21 08:05AM  
May-06-21 08:05AM  
May-05-21 04:35PM  
08:05AM  
May-03-21 08:05AM  
Apr-28-21 08:05AM  
Mar-30-21 02:23AM  
Mar-25-21 08:05AM  
Mar-22-21 04:05PM  
Mar-15-21 09:11AM  
08:05AM  
Mar-11-21 08:05AM  
Feb-24-21 08:05AM  
Feb-19-21 01:25PM  
Feb-16-21 10:00PM  
05:19PM  
Feb-02-21 07:30AM  
Jan-28-21 08:05AM  
Jan-26-21 04:05PM  
Jan-15-21 08:05AM  
Jan-05-21 08:05AM  
Dec-29-20 11:46PM  
Dec-07-20 08:05AM  
Nov-16-20 08:05AM  
Nov-06-20 08:35AM  
Oct-09-20 08:00AM  
Sep-16-20 08:05AM  
Sep-09-20 08:00AM  
07:23AM  
Sep-08-20 08:05AM  
Aug-06-20 08:35AM  
Aug-05-20 05:45PM  
Aug-03-20 09:00AM  
Jul-31-20 07:35AM  
Jul-30-20 07:35AM  
Jul-29-20 07:05AM  
Jul-07-20 04:05PM  
Jul-03-20 07:12AM  
Jul-01-20 10:10PM  
Jun-25-20 08:00AM  
Jun-08-20 08:05AM  
Jun-04-20 04:05PM  
May-15-20 04:45PM  
May-08-20 09:00AM  
May-06-20 08:05AM  
May-03-20 07:30PM  
Apr-30-20 03:08PM  
Apr-15-20 04:06PM  
09:15AM  
Apr-07-20 01:00PM  
Apr-06-20 09:00AM  
Apr-03-20 10:36AM  
Mar-30-20 05:00PM  
Mar-12-20 08:00AM  
Feb-21-20 02:00PM  
Feb-20-20 07:06AM  
Feb-19-20 07:00PM  
Feb-12-20 08:05AM  
Jan-28-20 08:00AM  
Jan-27-20 08:35AM  
Jan-09-20 08:39AM  
Jan-08-20 04:01PM  
Dec-30-19 06:38AM  
Dec-20-19 05:45PM  
Dec-18-19 09:00AM  
Dec-16-19 09:00AM  
Nov-07-19 06:28PM  
Nov-05-19 07:56AM  
Oct-29-19 10:33AM  
Oct-08-19 09:00AM  
Oct-04-19 04:59PM  
Sep-26-19 06:34AM  
Sep-24-19 04:01PM  
Sep-20-19 11:00AM  
Aug-20-19 11:16PM  
Aug-13-19 05:45PM  
04:15PM  
Aug-01-19 10:33AM  
Jul-01-19 10:30AM  
Jun-06-19 02:06PM  
May-08-19 06:04PM  
May-07-19 07:25PM  
06:22PM  
05:12PM  
May-02-19 10:02AM  
Apr-29-19 10:31AM  
Mar-26-19 07:50PM  
05:22PM  
Mar-19-19 08:00AM  
Mar-18-19 11:18AM  
Mar-13-19 07:27AM  
Mar-12-19 04:32PM  
Mar-04-19 08:58AM  
Feb-27-19 09:57AM  
Feb-26-19 08:55AM  
Feb-14-19 10:45AM  
Feb-13-19 08:36AM  
Jan-29-19 09:30AM  
08:48AM  
Jan-16-19 09:03AM  
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.